Benign Prostatic Hyperplasia — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for benign prostatic hyperplasia. 4 active patents protecting 1 drugs from 1+ originators. First major cliff: 2038. Daily refresh.

1
Approved drugs
4
Active US patents
73/100
Avg vulnerability
—
Annual revenue covered

Originators in Benign Prostatic Hyperplasia

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Eli Lilly 4 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating benign prostatic hyperplasia. Each bar = one year. Y-axis scaled to peak year (4 patents).

4
38

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Cialis
tadalafil
 Eli Lilly 4 73 — 2038-12-24

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12186322 Cialis method of use 75 2038-12-24
11975006 Cialis method of use 75 2038-12-24
11666576 Cialis method of use 70 2038-12-24
11382917 Cialis method of use 70 2038-12-24

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11666576 Cialis method of use 70 2038-12-24
11382917 Cialis method of use 70 2038-12-24
12186322 Cialis method of use 75 2038-12-24
11975006 Cialis method of use 75 2038-12-24

Related